Litcius/Paper detail

A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa

Rebecca Jepsen, Chloe Edwards, Akshay Flora, Emily Kozera, John W. Frew

2023Journal of the American Academy of Dermatology34 citationsDOI

Topics & Concepts

MedicineHidradenitis suppurativaSykAdverse effectInternal medicineDermatology Life Quality IndexTolerabilityDermatologyPsoriasisTyrosine kinaseDiseaseReceptorHidradenitis Suppurativa and TreatmentsAutoimmune and Inflammatory DisordersAcne and Rosacea Treatments and Effects
A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa | Litcius